In vitro and in vivo modulation of cartilage degradation by a standardized Centella asiatica fraction.
Osteoarthritis (OA) is a degenerative joint disease in which focal cartilage destruction is one of the primary features. The present study aims to evaluate the effect of a Centella asiatica fraction on in vitro and in vivo cartilage degradation. Bovine cartilage explants and bovine chondrocytes cultured in alginate were stimulated with IL-1 beta in the presence or absence of different concentrations (2, 5 and 10 microg/ml) of a standardized Centella asiatica triterpenes (CAT) fraction. The CAT fraction inhibited the IL-1 beta-induced proteoglycan (PG) release and nitric oxide (NO) production by cartilage explants in a dose-dependent manner. The IL-1 beta-induced reduction in PG synthesis and proliferation of chondrocytes cultured in alginate were counteracted by the CAT fraction at a concentration of 10 microg/ml. In a zymosan-induced acute arthritis model, the CAT fraction inhibited PG depletion without modulating joint swelling and inflammatory cell infiltration. In conclusion, the present study demonstrated for the first time that the tested Centella asiatica fraction was able to inhibit the zymosan-induced cartilage degradation in vivo without affecting the zymosan-induced inflammatory cell infiltration and joint swelling. The in vitro data indicate that the cartilage protective activity might at least partially be induced by the inhibition of NO production. The overall results indicate a possible disease modifying osteoarthritic activity of the Centella asiatica fraction.
Hartog
Anita
A
Danone Research, Centre for Specialised Nutrition, P.O. Box 7005, 6700 CA Wageningen, The Netherlands. anita.hartog@danone.com
Smit
H Friso
HF
van der Kraan
Peter M
PM
Hoijer
Maarten A
MA
Garssen
Johan
J
D000818:Animals; D002356:Cartilage / Q000378:metabolism*; D002417:Cattle; D049109:Cell Proliferation / Q000187:drug effects*; D002478:Cells, Cultured; D028041:Centella; D019902:Chondrocytes / Q000378:metabolism* / Q000473:pathology; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D005260:Female; D053583:Interleukin-1beta / Q000494:pharmacology; D051379:Mice; D009569:Nitric Oxide / Q000096:biosynthesis; D020370:Osteoarthritis, Knee / Q000139:chemically induced / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control*; D010936:Plant Extracts; D011509:Proteoglycans / Q000096:biosynthesis; D014315:Triterpenes / Q000494:pharmacology*; D015054:Zymosan / Q000633:toxicity
C526146:Centella asiatica extract; D053583:Interleukin-1beta; D010936:Plant Extracts; D011509:Proteoglycans; D014315:Triterpenes; D009569:Nitric Oxide; D015054:Zymosan